Intraarticular Steroids, Saline and Occupational Therapy in People With CMC1 Osteoarthritis

Last updated: June 25, 2025
Sponsor: Diakonhjemmet Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Osteoarthritis

Treatment

Injection of triamcinolone acetonide into the CMC-1 joint

Multimodal Occupational therapy for CMC-1 joint OA

Placebo

Clinical Study ID

NCT06084364
2023-505254-17-00
  • Ages 40-85
  • All Genders

Study Summary

A placebo-controlled randomized controlled trial exploring the effect of intraarticular steroids, saline or an occupational therapy intervention in inflammatory carpometacarpal-1 osteoarthritis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult (40-85 years of age) men and women

In target joint:

  • OA confirmed by radiographs or ultrasound examination

  • Inflammation by ultrasound (grey scale synovitis grade 1-3)

  • Pain of at least 3 on a 0-10 Numeric Rating Scale (NRS) at rest or during activitiesat both pre-screening and screening.

  • Patient is assessed as eligible for the proposed use of Kenacort-T

Exclusion

Exclusion Criteria:

  • Use of thumb orthosis on most of the days or structured hand exercises in the last 12 weeks

  • Intraarticular injections in the target CMC-1 joint in the last 12 weeks

  • More than 3 previous IACS in the target CMC-1 joint

  • Use of oral or intramuscular steroids in the last 12 weeks

  • Previous surgery of the target CMC-1 joint

  • Planned hand surgery in the coming 24 weeks

  • Do not want to quit using oral or topical NSAIDs (such as ibuprofen, diclofenac,etoricoxib, naproxen) in the next 12 weeks

  • Systemic inflammatory joint diseases (such as rheumatoid arthritis (RA), psoriaticarthritis or gout) or other conditions that can better explain the hand pain (suchas thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, handinjury in previous six months, or palmar tenosynovitis/trigger finger)

  • Diagnosis of fibromyalgia

  • Diagnosis of psoriasis

  • Infection, skin disease or wounds at joint injection site

  • Serious comorbidities, cognitive dysfunction, substance/alcohol abuse or any othermedical condition that makes adherence to the study protocol difficult

  • Known hypersensitivity to Triamcinolone acetonide (Kenacort) or any of theexcipients (sodium carboxymethylcellulose, sodium chloride, polysorbate, benzylalcohol, sodium hydroxide or hydrochloric acid)

  • Included in another clinical study

  • Use of digitalis glycosides

  • Patients vaccinated or immunized with live virus vaccines in the last 2 weeks

  • Not being able to talk or understand Norwegian

  • Known pregnancy or planned pregnancy in the next 6 months

  • Any condition that in the view of the investigator would suggest that the patient isunable to comply with the study protocol and procedures

Study Design

Total Participants: 354
Treatment Group(s): 3
Primary Treatment: Injection of triamcinolone acetonide into the CMC-1 joint
Phase: 4
Study Start date:
November 03, 2023
Estimated Completion Date:
November 30, 2028

Study Description

The primary aim of the PICASSO trial is to examine the efficacy and safety of intraarticular corticosteroid injections and a multimodal occupational therapy intervention in patients with CMC-1 OA (Phase 1). By comparing available non-pharmacological and pharmacological treatments head-to-head, our results will be of interest to the range of health professionals who are involved in the management of CMC-1 OA patients. By including patients who are likely to benefit from the intervention (painful and inflammatory CMC-1 OA), appropriate dosage of drug and ultrasound-guided injections, our trial is more guarded against possible false negative results than previous studies. We will also explore predictors for treatment effects. Due to the heterogeneous presentation of OA, it is unlikely that one treatment will fit all, and treatment should be tailored to the patients´ clinical presentation. Second, we will explore the long-term safety of IACS, and whether the occupational therapy intervention can prevent or halt CMC-1 subluxation (Phase 2).

Connect with a study center

  • Nordlands Hospital

    Bodø,
    Norway

    Active - Recruiting

  • Haugesund Rheumatism Hospital

    Haugesund,
    Norway

    Active - Recruiting

  • Diakonhjemmet Hospital

    Oslo,
    Norway

    Active - Recruiting

  • Martina Hansens Hospital

    Sandvika,
    Norway

    Active - Recruiting

  • Stavanger University Hospital

    Stavanger,
    Norway

    Active - Recruiting

  • St Olavs Hospital

    Trondheim,
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.